|
Dr. Alan Feiger
Dr. Alan Feiger is a Board Certified Psychiatrist who has devoted the last twenty years of his life to clinical research in the development of a wide variety of medications used to treat psychiatric and other medical disorders. He is on the faculty at the University of Colorado Health Sciences Center serving as an Associate Professor of Psychiatry. He has lectured locally and throughout the world at numerous prestigious conferences. In the industry, he is respected as a careful and precise clinical researcher. Numerous pharmaceutical companies have contracted with him to perform clinical studies. To the volunteers in his studies he is known as a caring physician who listens carefully and respects volunteers for their dedication to advancing medical knowledge. Dr. Feiger sees each patient at most visits. Recently (9/02) he has added another staff psychiatrist to see patients when his duties or travel require him to be away from the office. |
|
3555 LUTHERAN PARKWAY, SUITE 320 WHEAT RIDGE, COLORADO 80033 TELEPHONE: (303) 425-4249 FAX: (303) 425-4303 – al@feigerresearch.com ______________________________________________________________________________ Medical Director of the Feiger Health Research Center Associate Clinical Professor, Department of Psychiatry, University of Colorado Private Practitioner of Psychiatry Specializing in Psychopharmacology Consultant to the Pharmaceutical Industry Partner – Research Training Associates Member of the Board – HealthCare Technology Certified in Psychiatry, American Board of Psychiatry and Neurology, 1976 Psychiatric Residency, University of Colorado Health Sciences Center, 1971-1974 Medicine Internship, Los Angeles County Hospital, 1970-1971 M.D., University of Southern California, 1970 B.A., Brandeis University, 1966 CLINICAL TRIALS FOR DEPRESSION: Wyeth-Ayerst, desvenlafaxine, DB vs. placebo, 2003 – con’t. Wyeth-Ayerst, desvenlafaxine open label, 2003 – con’t. Somerset, selegiline transdermal open label, 2003 – con’t. Organon, ORG 33062 Open Label, 2002 – con’t Organon, ORG 33062 vs. fluoxetine and placebo, 2002 – 2003 Somerset, selegiline transdermal open label, 2002 – 2003 Somerset, selegiline transdermal vs. placebo, 2002. Wyeth-Ayerst, venlafaxine ER vs. sertraline vs. placebo, 2001. Bristol-Myers Squibb, nefazodone ER vs. sertraline and placebo, 2000. Eli Lilly, r-fluoxetine vs. fluoxetine and placebo, 2000. Organon, ORG 33062 ER vs. placebo, 1999 – 2000. Bristol Myers Squibb, nefazodone ER vs. paroxetine and placebo, 1999 – 2000 Merck, L-759274, DB vs. paroxetine and placebo, 1998 – 1999 Eli Lilly, duloxetine, DB vs. fluoxetine and placebo, 1999. Boehringer Ingelheim, flibanserin, DB comparison paroxetine and placebo, 1997-98 Organon, Remeron, relapse prevention vs. placebo, 1997-98. Eli Lilly, fluoxetine, DB fluoxetine plus pindalol vs. fluoxetine vs. placebo, 1997. Smith-Kline Beecham, paroxetine MR, DB vs. paroxetine IR vs. placebo, 1996. Eli Lilly, fluoxetine, DB fluoxetine plus pindalol vs. fluoxetine vs. placebo, 1996. Wyeth Ayerst, venlafaxine ER, DB vs. placebo for prevention of relapse, 1996. Bristol Myers Squibb, nefazodone, DB fixed dose vs. placebo, 1996. Wyeth Ayerst, venlafaxine ER, DB comparison fluoxetine and placebo, 1995-96. Organon, ORG 4428, DB comparison fluoxetine and placebo, continuation therapy with placebo substitution, 1995. Bristol Myers Squibb, BMS 101, DB vs. placebo, 1995. Wyeth Ayerst, venlafaxine ER, DB vs. placebo, 1994-95. Sano, buspirone, DB transdermal patch vs. placebo, 1994-95. Solvay, fluvoxamine, DB comparison paroxetine and placebo, 1994. Pfizer, tandospirone GITS, DB dose ranging vs. placebo, 1993-94. Bristol Myers Squibb, nefazodone, DB comparison sertraline, 1993-94. Eli Lilly, fluoxetine, open-label switch from sertraline, 1993. Bristol Myers Squibb, nefazodone, DB vs. placebo for continuation therapy, 1992-95. Pfizer, sertraline, DB comparison fluoxetine, 1992. Smith-Kline Beecham, paroxetine, switch from fluoxetine without washout, 1992. Smith-Kline Beecham, paroxetine, DB comparison fluoxetine and placebo, 1991. Bristol Myers Squibb, gepirone-ER, DB comparison imipramine and placebo, 1991-92. Bristol Myers Squibb, buspirone, DB comparison imipramine and placebo, 1990-92. Pfizer, tandospirone, DB dose ranging vs. placebo, 1990. DEPRESSION TRIALS (CON’T) Bristol Myers Squibb, buspirone, open-label, 1989. McNeil, etoperidone, DB vs. imipramine, 1988. McNeil, etoperidone, DB vs. amitriptyline, 1988. Organon, mirtazepine, long term tolerability, 1987. Smith-Kline Beecham, paroxetine, long term, 1986-87. Burroughs Wellcome, buproprion, long term tolerability, 1982. CLINICAL TRIALS FOR SCHIZOPHRENIA: Pfizer, ziprasidone, DB comparison haloperidol, 1995 - 1998. Eli Lilly, olanzapine, DB comparison haloperidol, 1994. Sandoz, clozapine, humanitarian, 1987. CLINICAL TRIALS FOR INSOMNIA: Wyeth Ayerst, zaleplon, DB dose ranging vs. placebo, 1996. Wyeth Ayerst, zaleplon, open label for insomnia, 1996. Bristol-Myers Squibb, BMS-214778 DB vs. placebo in the Elderly, 1998 CLINICAL TRIALS FOR ALZHEIMER'S: Smith-Kline Beecham, oxiracetam, DB vs. placebo, 1990. CLINICAL TRIALS FOR MIGRAINES: Glaxo, oral naratriptan, DB vs. placebo for subjects who did not respond to oral sumatriptan, 1997. Glaxo, sumatriptan suppository, DB vs. placebo for multiple migraines, 1993. CLINICAL TRIALS FOR SOCIAL PHOBIA: Wyeth-Ayerst, venlafaxine vs. placebo, 2000 – 2001. Ciba-Geigy, brofaromine, DB vs. placebo, 1992. Glaxo, ondansetron, DB vs. placebo, 1992. CLINICAL TRIALS FOR DISORDERS IN CHILDREN: Bristol-Myers Squibb, buspirone transdermal patch vs. placebo for ADHD, 1997-98. Bristol-Myers Squibb, buspirone transdermal patch open label for ADHD, 1997-98. CLINICAL TRIALS FOR GENERALIZED ANXIETY DISORDER: Sandoz, abecarnil, open-label safety, 1991. Glaxo, ondansetron, DB dose ranging vs. placebo, 1990. Miles, ipsapirone, DB comparison lorazepam and placebo, 1988. Pfizer, tandospirone, DB vs. placebo, 1988. CLINICAL TRIALS FOR BIPOLAR I DISORDER: Glaxo, lamotrigine, DB vs. Lithium and placebo, relapse prevention of depression and mania, 1997 –1999. CLINICAL TRIALS FOR PANIC DISORDER: Bristol-Myers Squibb, nefazodone, DB vs. placebo, 1997 – 1998. Smith-Kline Beecham, paroxetine modified release, DB vs. placebo, 1996. Smith-Kline Beecham, paroxetine, DB vs. placebo, 1993. Smith-Kline Beecham, paroxetine, DB dose ranging vs. placebo, 1990. Pfizer, tandospirone, DB vs. placebo, 1988. CLINICAL TRIALS FOR OBSESSIVE COMPULSIVE DISORDER: Pfizer, Computer Assisted vs. Clinician Administered Behavior Therapy, 1996 – 1998. Pfizer, sertraline, DB dose ranging vs. placebo, 1988. Ciba Geigy, clomipramine, DB vs. placebo, 1986. CLINICAL TRIALS FOR SMOKING CESSATION: Ciba Geigy, Habitrol, DB vs. placebo, 1989. CLINICAL TRIALS FOR HYPERTENSION: Bristol-Myers Squibb, omapatrilat vs. enalapril, 2000 – 2001. CLINICAL TRIALS FOR TYPE II DIABETES GlaxoSmith Kline, rosiglitazone in parallel with glyburide on Cognition in Type 2 Diabetes, 2001 - 2002 Trainer in Research Methodology Partner in Research Training Associates – A consulting firm with Ken Kobak, Ph.D., and Josh Lipsitz, Ph.D., to facilitate better training at pharmaceutical start-up meetings in research of depression/anxiety. (Research Training Associates is a national consortium of experts offering several model training packages designed to establish inter-rater reliability in multi-site clinical trials on the HAMD< HAMA< SCID, and other rating scales.) “Gepirone Extended Release (ER): New Evidence for Efficacy in the Treatment of Major Depressive Disorder,” by Alan D. Feiger, M.D., Jon F. Heiser, M.D., et al, In Press. “Impact of a Comprehensive HAMD Inter-Rater Reliability Training in a Multi-Site Trial,” by Alan D. Feiger, M.D., Joshua D. Lipsitz, Ph.D., et al, In Press. "A Multicenter, Double-Blind, Placebo-Controlled Study of Nefazodone in the Continuation Treatment of Outpatients with Major Depression," by Alan D. Feiger, M.D., Robert Bielski, M.D., James Bremner, M.D., John Heiser, M.D., Madhukai Trivedi, M.D., and Charles Wilcox, Ph.D., International Clinical Psychopharmacology, vol. 14, no. 1, 1999. "Nefazodone Versus Sertraline in Outpatients with Major Depression: Focus on Efficacy, Tolerability, and Effects on Sexual Function and Satisfaction," by Alan Feiger, M.D., Ari Kiev, M.D., Ram K. Shrivastava, M.D., and Peter G. Wisselink, M.D. and Charles Wilcox, Ph.D. Journal of Clinical Psychiatry, vol. 57 supplement, 1996. "A Double-Blind Comparison of Paroxetine and Fluvoxamine in Major Depressive Disorder," by Ari Kiev, M.D. and Alan Feiger, M.D. Journal of Clinical Psychiatry, vol.58:4 supplement, April 1997. "A Double-Blind Comparison of Gepirone Extended Release, Imipramine, and Placebo in Treatment of Outpatient Major Depression" by Alan Feiger, M.D. Psychopharmacology Bulletin, vol. 32, no. 4, 1996. "A Double-Blind, Randomized, Placebo-Controlled Trial of Once-Daily Venlafaxine XR and Fluoxetine for the Treatment of Depression" by Richard L. Rudolph, M. D., and Alan Feiger, M.D. Journal of Affective Disorders, 2/2000. PUBLICATIONS (CON’T) Psychiatric Decision Making, by Steve Dubovsky, M.D., Ben Eiseman, M.D., and Alan Feiger, M.D. A reference book published by Decker, 1984, which contains a collection of decision-making trees for common psychiatric problems confronted by physicians. The book is currently published in English, Indonesian, Japanese, and Spanish. Chapters authored by Dr. Feiger include: - Psychiatric Management of Suicide Attempts - General Approach to Anxiety - Somatic Treatment of Anxiety - Acute Psychosis - Management of Chronic Schizophrenia - Tricyclic Resistant Depression - Incipient Schizophrenia Psychosis "Masked Depression in the Elderly," edited by Martin Carl Peper, CIBA Pharmaceuticals, 1984. "Biological Testing in Psychiatry: Psychiatric Clinical Update," Upjohn, October, 1983. "Emotional Problems in Dissolution of Marriage Cases," by Alan Feiger, M.D. and Lynn D. Feiger. The Colorado Lawyer, June, 1976. "Monkey Motor Stimulation and Altered Social Behavior During Chronic Methadone Administration," Crowley, et.al., Psychopharmacology, Vol. 43, 1975. Dr. Feiger has been a speaker in over 150 symposia to psychiatrists, lay public, primary care physicians and the pharmaceutical industry. He has lectured throughout the USA, Canada, Sweden, Norway, Spain, France, Germany, Korea, Saudi Arabia, Lebanon, Jordan, Kuwait, Bahrain, United Emirates Republic, and Jamaica. In addition to presenting his own research findings and reviewing world literature on areas of his expertise, Dr. Feiger emphasizes practical applications for clinicians. To facilitate dialogue with clinicians, he uses videotapes of actual patients, humor and querying the audience. He has been quoted in the Washington Post, London Times, Wall Street Journal, New York Times, and on CNN. Some of his topics include: - Sexual Dysfunction in Depressive Disorders - Custom Tailoring an Antidepressant Regime - New Antidepressants - Continuation Therapy for Depression - Methodology of Clinical Trials - Standardizing the Hamilton Depression Scale - Differential Diagnosis of Depression - Psychoeconomics - Panic Disorder: Diagnosis and Treatment - The Biology and Treatment of Obsessive Compulsive Disorder - Serotonin: Violence and Type II Alcoholism Director of the Feiger Health Research Center, 1996-present. Associate Professor of Psychiatry, C.U. Health Science Center. Consultant on drug development for many international pharmaceutical companies. Member of Exempla Institutional Review Board, 1999-Present. M.D. of Research Training Associates (An organization to improve reliability in clinical trials) Task Force Member of Placebo Response Team (Key opinion leaders from research organizations and pharmaceutical industry) Director of the Feiger PsychMed Center, 1990-96. Co-director of the Rocky Mountain Center for Biologic Psychiatry, 1986-89. Private practice, psychiatry, 1974-present. Practice emphasis in psychopharmacology, biologic psychiatry and psychiatric diagnosis. Psychopharmacology consultant for the psychiatric community throughout the Denver metropolitan area. Examiner, American Board of Psychiatry and Neurology. Member, Lutheran Hospital Institutional Review Board, 1994-1998. Pro Bono Volunteer Jefferson County Action Center, 1996-1998. Vice President of the Department of Behavioral Sciences, Exempla, 1998. Secretary, West Pines Psychiatric Hospital, 1988. Chairman, Committee of Therapeutics, West Pines Psychiatric Hospital, 1988. Consultant, Lutheran Medical Center Eating Disorders Clinic, 1986. Psychiatric Consultant, Denver Federal Center, 1980-85. Psychiatric Director for Colorado Department of Corrections (responsible for incarcerated violent adolescents), 1976-79. Psychiatric Director Adolescent Services, Fort Logan, 1974-76. Supervised by Maxwell Jones, M.D. in Principles of Therapeutic Community, 1974. Admin\resume\feigerCV Updated 1/04 |